Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Executive Summary

Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
Advertisement

Related Content

Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
FDA Needs Bigger Window To The Public, Say Deputies
Ovarian cancer endpoints workshop
Composite Brain Tumor Endpoint Could Include Patient-Reported Outcomes
Oncology Committee On Brain Tumor Endpoints Planned For Summer – Pazdur
Oncology Committee On Brain Tumor Endpoints Planned For Summer – Pazdur
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Leukemia Trials Need Broader Populations, FDA/ASH Workshop Suggests
Advertisement
UsernamePublicRestriction

Register

PS046838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel